Cejemly
What Cejemly is used for
Cejemly in combination with platinum-based chemotherapy is indicated for the first line treatment of adults with metastatic non small cell lung cancer (NSCLC) with no sensitising EGFR mutations, or ALK, ROS1 or RET genomic tumour aberrations. Cejemly as monotherapy is indicated for the treatment of unresectable stage III NSCLC with no sensitising EGFR mutations, or ALK, ROS1 genomic tumour aberrations in adults whose tumours express PD-L1 on ≥ 1% of tumour cells and whose disease has not progressed following platinum-based chemoradiotherapy.
Approved use, as published by the European Medicines Agency.
Key facts
- Brand
- Cejemly
- Active substance
- sugemalimab
- Disease area
- Carcinoma, Non-Small-Cell Lung
- Medicine group
- Antineoplastic agents;monoclonal antibodies and antibody drug conjugates;PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors
- ATC code
- L01FF11
- Marketing authorisation holder
- Cstone Pharmaceuticals Ireland Limited
- Authorised in the EU since
- 2024
Official information
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Cejemly used for?
Cejemly in combination with platinum-based chemotherapy is indicated for the first line treatment of adults with metastatic non small cell lung cancer (NSCLC) with no sensitising EGFR mutations, or ALK, ROS1 or RET genomic tumour aberrations. Cejemly as monotherapy is indicated for the treatment of unresectable stage III NSCLC with no sensitising EGFR mutations, or ALK, ROS1 genomic tumour aberrations in adults whose tumours express PD-L1 on ≥ 1% of tumour cells and whose disease has not progressed following platinum-based chemoradiotherapy.
What is the active substance in Cejemly?
Cejemly contains sugemalimab.
Who makes Cejemly?
The EU marketing authorisation holder is Cstone Pharmaceuticals Ireland Limited.
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU